Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

272 - Towards the identification of the mechanism of action of antitumor 1-methyl-D-tryptophan

Date

05 Mar 2018

Session

Poster display

Presenters

Maria Teresa Pallotta

Citation

Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047

Authors

M.T.O. Pallotta1, A. Iacono1, E. Albini1, C. Orabona1, M.L. Belladonna1, R. Bianchi1, A. Coletti2, F. Greco2, A. Macchiarulo2, U. Grohmann1

Author affiliations

  • 1 Dept. Experimental Medicine, University of Perugia, Dept Experimental Medicine, 06132 - Perugia/IT
  • 2 Dept. Pharmaceutical Sciences, University of Perugia, Dept Pharmaceutical Sciences, 06123 - Perugia/IT
More

Resources

Abstract 272

In recent years, tryptophan degradation has received increasing attention as a potent immunosuppressive mechanism involved in the maintenance of immunological tolerance in both tumor draining lymph nodes and tumors. Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme and its mechanisms of action as an immune regulator involves tryptophan deprivation, production of immunosuppressive metabolites (kynurenines), and activation of signaling events through binding of tyrosine phosphatases (SHPs). IDO1 is chronically activated in many cancer patients and its expression and enzyme activity correlate with a poor prognosis in patients with various cancers. In the past, IDO1 inhibition was mostly achieved using the racemic mixture of 1-D,L-methyltryptophan (1-MT). As it became apparent that IDO1 inhibition may be a promising target for cancer therapy, the individual stereoisomers of 1-MT were investigated in more details. 1-L-MT was shown to more effectively inhibit IDO1 in enzyme assays and in cancer cell lines. However, 1-D-MT showed superior anti-tumor activity in mouse models and was therefore chosen for clinical trials. 1-D-MT is currently being tested in phase II clinical trials (indoximod) as an adjunct to conventional chemotherapy, although its immunostimulatory mechanism is still unknown. We here investigated whether 1-D-MT could interfere with IDO1 signaling rather than catalytic activity.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings